On June 27th, Gelunhui reported that Sihuan Pharm (0460.HK) has obtained the drug registration certificate issued by the National Medical Products Administration for the hydroxybenzenesulfonic calcium capsule developed by its non-wholly-owned subsidiary Huisheng Biotech, which can be regarded as passing the consistency evaluation of generic drug quality and efficacy. Hydroxybenzenesulfonic calcium is a drug recommended in China's clinical guidelines for improving diabetes microcirculation. The hydroxybenzenesulfonic calcium capsule is included in the national medical insurance category B. The indications approved for this product are the treatment of microvascular diseases such as diabetic microvascular lesions - retinopathy and glomerulosclerosis, microvascular damage, etc.
四环医药附属微血管病药获准内地上市
Sihuan Pharm's microvascular disease drug has been approved for mainland China's market.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.